



UNIVERSITY OF LEEDS

This is a repository copy of *Feasibility of preference-driven radiotherapy dose treatment planning to support shared decision making in anal cancer*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/115742/>

Version: Supplemental Material

Article:

Rønde, HS, Wee, L, Pløen, J et al. (1 more author) (2017) Feasibility of preference-driven radiotherapy dose treatment planning to support shared decision making in anal cancer. *Acta Oncologica*, 56 (10). pp. 1277-1285. ISSN 0284-186X

<https://doi.org/10.1080/0284186X.2017.1315174>

© 2017 Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in *Acta Oncologica* on 27th April 2017, available online:
<http://www.tandfonline.com/10.1080/0284186X.2017.1315174>.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 1. Patient characteristics.

	Men (n=11)	Women (n=11)	Total (n=22)
T stage (T1/T2/T3/T4)	1/7/3/0	1/6/2/2	2/13/5/2
N stage (N0/N1/N2/N3)	5/1/4/1	6/1/3/1	11/2/7/2
Chemo-radiotherapy*	CISPLATIN		

Tumour/organ Volumes [cm^3]

PTV-T	158 (137-231)	130 (116-244)	156
PTV-N	2030 (1900-2257)	1931 (1719-2112)	2014
Bowel	1135 (893-1328)	1557 (1483-1698)	1406
Bladder	168 (114-267)	76 (50-169)	139

PTV: Planning Target Volume, T: Tumour, N: elective volume. For all continuous measures, median values are reported with interquartile ranges in brackets. * All patients received concurrent chemo-radiotherapy with CISPLATIN. Full list in online supplementary material Table e1.